On Location

On Location

Updates from major medical meetings in the field of hematology/oncology

Rusfertide Helps Patients With Polycythemia Vera Avoid Phlebotomy

Patients with polycythemia vera (PV) who received rusfertide were able to avoid therapeutic phlebotomy for seven months, even among those with high-risk disease, according...
On location

Venetoclax Added to Intensive Chemotherapy Is Safe, Effective in Relapsed/Refractory AML

In a study presented at EHA2021 Virtual, the annual congress of the European Hematology Association, adding short-term venetoclax to an intensive FLA-IDA chemotherapy regimen...
On location

Evaluating Maintenance Therapy After Fixed-Duration Obinutuzumab Plus Venetoclax in CLL

For patients with chronic lymphocytic leukemia (CLL) who are considered unfit for FCR chemotherapy (fludarabine, cyclophosphamide, rituximab), a fixed-duration regimen of venetoclax plus obinutuzumab...
On location

R-CHOP Versus R-EPOCH: No Difference in Survival for Patients With MYC-Rearranged, Double- or Triple-Hit...

Overall survival (OS) outcomes were similar between patients with MYC-rearranged diffuse large B-cell lymphoma (DLBCL) and double-hit lymphoma (DHL)/triple-hit lymphoma (THL) who were treated...
On location

Investigators Identify Distinct Molecular Subgroups to Guide Treatment Decisions in AML

Analyzing genetic data from more than 3,000 patients with acute myeloid leukemia (AML), researchers from Memorial Sloan Kettering Cancer Center identified 14 distinct molecular...
On location

Evaluating Enasidenib, With or Without Azacitidine, in Patients with IDH2-Mutated MDS

Enasidenib was had a tolerable safety profile and showed promising clinical activity in patients with IDH2-mutated, high-risk myelodysplastic syndromes (MDS), according to results from...
On location

Fixed-Duration Ibrutinib, Venetoclax Oral Combination Effective in CLL/SLL

A fixed-duration regimen of first-line ibrutinib plus venetoclax provided deep, durable responses in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), according to...
On location

Early Trial Shows Promising Results for Venetoclax Combination in Newly Diagnosed Mantle Cell Lymphoma

Adding venetoclax to rituximab and lenalidomide appeared to be safe and resulted in high rates of overall response and measurable residual disease (MRD) undetectability...
On location

PET-Adapted Therapy in Classical Hodgkin Lymphoma Allows Omission of Radiation Therapy

Patients with early-stage classical Hodgkin lymphoma (cHL) and bulky disease who achieved a response after two cycles of chemotherapy were able to avoid radiation...
On location

Olutasidenib Shows Promise for Relapsed/Refractory IDH1-Mutated Acute Myeloid Leukemia

Olutasidenib, an investigational IDH1 inhibitor selective for mutant IDH1, was well tolerated and associated with durable complete remissions (CRs) in patients with high-risk, relapsed/refractory...

Current Issue

June 2021 Volume 7 Issue 7

This issue reviews the management and prevention of peripheral neuropathy, early successes of SCD screening programs in sub-Saharan Africa, and more.

Block title